CML Patients Approach Normal Life Expectancy With Imatinib Treatment
Treatment with imatinib results in good overall survival in patients with chronic myeloid leukemia, approaching a normal life expectancy, according to the CML-IV study.
FDA Grants Priority Review for New Leukemia Option
The FDA has granted priority review status for two new indications of dasatinib (Sprycel), according to the drug’s developer.
Treatment-Free Remission in CML Sustainable After Nilotinib
Approximately half of patients with chronic-phase CML who achieved a sustained deep molecular response with nilotinib were able to discontinue therapy and remain in treatment-free remission through 96 weeks.
TKI De-escalation Safe in Most CML Patients With Major Molecular Response
A de-escalation of tyrosine-kinase inhibitor dose was safe in the majority of patients with chronic myeloid leukemia with stable major molecular response.
Dasatinib Is Safe, Effective in Pediatric Chronic Myeloid Leukemia
Dasatinib was safe and effective in pediatric patients with chronic myeloid leukemia, according to a new study, establishing the agent as a new standard of care for this population.
Frontline Bostunib vs Imatinib in Chronic Myeloid Leukemia
This video highlights results of the BFORE trial, which tested bosutinib vs imatinib in newly diagnosed chronic myeloid leukemia patients.
TKI Discontinuation Possible for Some CML Patients
Ahead of the 2017 ASCO Annual Meeting, we discuss the discontinuation of TKIs in some chronic myeloid leukemia patients.
Challenges in Molecular Monitoring for CML Treatment Response
This video examines the challenge in optimizing and standardizing molecular monitoring for patients with chronic myeloid leukemia.
By clicking Accept, you agree to become a member of the UBM Medica Community.